ArticleBMC pharmacology & toxicology2025
Differential effects of β-blockers nebivolol and metoprolol on mitochondrial biogenesis and antioxidant defense in angiotensin II-induced pathology in H9c2 cardiomyoblasts.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways.Frontiers in pharmacology · 2026Review
- A Narrative Review on Nitrate-Rich Diets as Adjuncts to Antihypertensive Therapy: Enhancing Treatment Efficacy via Oxidative Stress Modulation.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMitochondrial dysfunction and oxidative stress induced by overactivation of angiotensin II (Ang II) are major contributors to the progression of cardiovascular diseases (CVD). This study investigates the comparative effects of nebivolol, a third-generation β1-adrenergic blocker, and metoprolol, a second-generation β1-adrenergic blocker, on Ang II-induced mitochondrial impairment in H9c2 cardiomyoblasts.
methodsNebivolol and metoprolol mediated protective effects were demonstrated against Ang II-induced mitochondrial dysfunction in H9c2 cells. Intracellular reactive oxygen species (ROS) production was assessed by detecting 2',7'-dichlorofluorescein (DCF) fluorescence. Western blotting and Real-time PCR were used to quantify protein and mRNA levels, respectively.
resultsOur results showed that both nebivolol and metoprolol significantly attenuated Ang II-induced ROS generation and the expression of apoptotic and proinflammatory genes. However, nebivolol demonstrated higher efficacy than metoprolol in suppressing the expression of the proapoptotic marker BNIP3, while upregulating the antioxidant defense system and anti-apoptotic BCL2 expression. Additionally, nebivolol enhanced the mitochondrial biogenesis and fusion related gene expression.
conclusionIn conclusion, both nebivolol and metoprolol effectively reduce oxidative stress and expression of proinflammatory genes in response to Ang II. However, nebivolol provides increased protection by restoring the antioxidant defense system and mitochondrial functions, highlighting its potential therapeutic advantage in Ang II-induced cardiac pathology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.